141 related articles for article (PubMed ID: 7946582)
1. Prognosis and treatment of T1G3 bladder tumours. A prognostic factor analysis of 121 patients. Dutch South Eastern Bladder Cancer Study Group.
Mulders PF; Hoekstra WJ; Heybroek RP; Schapers ER; Verbeek AL; Oosterhof GO; Debruyne FM
Eur J Cancer; 1994; 30A(7):914-7. PubMed ID: 7946582
[TBL] [Abstract][Full Text] [Related]
2. Prognostic factors in pTa-pT1 superficial bladder tumours treated with intravesical instillations. The Dutch South-Eastern Urological Collaborative Group.
Mulders PF; Meyden AP; Doesburg WH; Oosterhof GO; Debruyne FM
Br J Urol; 1994 Apr; 73(4):403-8. PubMed ID: 8199828
[TBL] [Abstract][Full Text] [Related]
3. Female gender and carcinoma in situ in the prostatic urethra are prognostic factors for recurrence, progression, and disease-specific mortality in T1G3 bladder cancer patients treated with bacillus Calmette-Guérin.
Palou J; Sylvester RJ; Faba OR; Parada R; Peña JA; Algaba F; Villavicencio H
Eur Urol; 2012 Jul; 62(1):118-25. PubMed ID: 22101115
[TBL] [Abstract][Full Text] [Related]
4. [Establishment of the prognostic evaluation system of T1G3 bladder urothelial cancer].
Li XD; Sun G; Liu XQ
Zhonghua Wai Ke Za Zhi; 2013 Aug; 51(8):741-5. PubMed ID: 24252684
[TBL] [Abstract][Full Text] [Related]
5. TUR and adjuvant intravesical chemotherapy in T1G3 bladder tumors: recurrence, progression and survival in 137 selected patients followed up to 20 years.
Serretta V; Pavone C; Ingargiola GB; Daricello G; Allegro R; Pavone-Macaluso M
Eur Urol; 2004 Jun; 45(6):730-5; discussion 735-6. PubMed ID: 15149744
[TBL] [Abstract][Full Text] [Related]
6. Tumor multiplicity is an independent prognostic factor of non-muscle-invasive high-grade (T1G3) bladder cancer.
Nakai Y; Nonomura N; Kawashima A; Mukai M; Nagahara A; Nakayama M; Takayama H; Nishimura K; Okuyama A
Jpn J Clin Oncol; 2010 Mar; 40(3):252-7. PubMed ID: 19995789
[TBL] [Abstract][Full Text] [Related]
7. [Conservative treatment of high-risk (T1G3) transitional carcinoma].
Catanzaro F; Torelli F; Catanzaro M; Cappellano F; Pizzoccaro M; Baruffi M; Sironi D; Pozzoli GL
Arch Ital Urol Androl; 1996 Feb; 68(1):21-4. PubMed ID: 8664915
[TBL] [Abstract][Full Text] [Related]
8. Results of transurethral resection and intravesical doxorubicin prophylaxis in patients with T1G3 bladder cancer.
Bono AV; Benvenuti C; Damiano G; Lovisolo J
Urology; 1994 Sep; 44(3):329-34; discussion 334-5. PubMed ID: 8073548
[TBL] [Abstract][Full Text] [Related]
9. Second transurethral resection and prognosis of high-grade non-muscle invasive bladder cancer in patients not receiving bacillus Calmette-Guérin.
Angulo JC; Palou J; García-Tello A; de Fata FR; Rodríguez O; Villavicencio H
Actas Urol Esp; 2014 Apr; 38(3):164-71. PubMed ID: 24613147
[TBL] [Abstract][Full Text] [Related]
10. Is it possible to stop follow-up of patients with primary T1G3 urothelial carcinoma of the bladder managed with intravesical bacille Calmette-Guérin immunotherapy?
Golabek T; Palou J; Rodríguez O; Gaya JM; Breda A; Villavicencio H
World J Urol; 2017 Feb; 35(2):237-243. PubMed ID: 27277599
[TBL] [Abstract][Full Text] [Related]
11. [Bladder preservation or initial cystectomy in T1G3 bladder cancer: which parameters help in therapeutic decision-making?].
Denzinger S; Burger M; Fritsche HM; Ganzer R; Blana A; Wieland WF; Otto W
Aktuelle Urol; 2008 Jan; 39(1):58-61; discussion 62-3. PubMed ID: 18228189
[TBL] [Abstract][Full Text] [Related]
12. [Does the initial or secondary status of T1G3 bladder tumours have a prognostic impact?].
Ouaki F; Irani J; Pires C; Breton X; Levillain P; Doré B
Prog Urol; 2006 Feb; 16(1):40-4. PubMed ID: 16526538
[TBL] [Abstract][Full Text] [Related]
13. An updated critical analysis of the treatment strategy for newly diagnosed high-grade T1 (previously T1G3) bladder cancer.
Kulkarni GS; Hakenberg OW; Gschwend JE; Thalmann G; Kassouf W; Kamat A; Zlotta A
Eur Urol; 2010 Jan; 57(1):60-70. PubMed ID: 19740595
[TBL] [Abstract][Full Text] [Related]
14. [T1G3 bladder tumors: our experience].
Pagano S; Franzoso F; Pachera F; Ruggeri P; Sorboli G
Arch Ital Urol Androl; 1996 Feb; 68(1):39-45. PubMed ID: 8664920
[TBL] [Abstract][Full Text] [Related]
15. Do molecular biomarkers have prognostic value in primary T1G3 bladder cancer treated with bacillus Calmette-Guerin intravesical therapy?
Park J; Song C; Shin E; Hong JH; Kim CS; Ahn H
Urol Oncol; 2013 Aug; 31(6):849-56. PubMed ID: 21782482
[TBL] [Abstract][Full Text] [Related]
16. Can re-cTURBT be useful in pT1HG disease as a risk indicator of recurrence and progression? A single centre experience.
Giulianelli R; Gentile BC; Mirabile G; Albanesi L; Tariciotti P; Rizzo G; Buscarini M; Vermiglio M
Arch Ital Urol Androl; 2017 Dec; 89(4):272-276. PubMed ID: 29473376
[TBL] [Abstract][Full Text] [Related]
17. Prognostic factors and risk groups in T1G3 non-muscle-invasive bladder cancer patients initially treated with Bacillus Calmette-Guérin: results of a retrospective multicenter study of 2451 patients.
Gontero P; Sylvester R; Pisano F; Joniau S; Vander Eeckt K; Serretta V; Larré S; Di Stasi S; Van Rhijn B; Witjes AJ; Grotenhuis AJ; Kiemeney LA; Colombo R; Briganti A; Babjuk M; Malmström PU; Oderda M; Irani J; Malats N; Baniel J; Mano R; Cai T; Cha EK; Ardelt P; Varkarakis J; Bartoletti R; Spahn M; Johansson R; Frea B; Soukup V; Xylinas E; Dalbagni G; Karnes RJ; Shariat SF; Palou J
Eur Urol; 2015 Jan; 67(1):74-82. PubMed ID: 25043942
[TBL] [Abstract][Full Text] [Related]
18. Multiplicity and history have a detrimental effect on survival of patients with T1G3 bladder tumors selected for conservative treatment.
Serretta V; Ruggirello A; Dispensa N; Allegro R; Aragona F; Melloni D
J Urol; 2008 Sep; 180(3):886-90; discussion 891. PubMed ID: 18635223
[TBL] [Abstract][Full Text] [Related]
19. The management of T1G3 bladder cancer.
Bogdanović J; Marusić G; Djozić J; Sekulić V; Budakov P; Dejanović N; Stojkov J
Urol Int; 2002; 69(4):263-5. PubMed ID: 12444280
[TBL] [Abstract][Full Text] [Related]
20. Intravesical bacille Calmette-Guérin in Stage T1 grade 3 bladder cancer therapy: a 7-year follow-up.
Hurle R; Losa A; Manzetti A; Lembo A
Urology; 1999 Aug; 54(2):258-63. PubMed ID: 10443721
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
